Company overview
UPM Biomedicals is a leading producer of patented nanofibrillar cellulose technology derived from birch wood pulp for medical and life science applications. The company manufactures animal-free biomaterials under ISO 13485 quality management systems for 3D cell culture, drug discovery, tissue engineering, advanced wound care, implants, and personalized medicine. Their product portfolio includes FibGel, the world's first injectable nanocellulose hydrogel for permanent implantable medical devices, launched in October 2024.
Nanofibrillar Cellulose for Life Sciences is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include nanofibrillar cellulose, 3d cell culture, biomedical materials, tissue engineering, injectable hydrogel, drug discovery.
Products and technologies associated with Nanofibrillar Cellulose for Life Sciences include Cell Culture — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.upm.com/en/business/biomedicals/
- Markets served
- United States & Americas
- Keywords
- nanofibrillar cellulose, 3d cell culture, biomedical materials, tissue engineering, injectable hydrogel, drug discovery, iso 13485, animal-free biomaterials, implantable medical devices, personalized medicine
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Frequently asked questions
- What is UPM Biomedicals' core technology?
- UPM Biomedicals specializes in nanofibrillar cellulose (NFC) technology derived from birch wood pulp. This patented, animal-free biomaterial is biocompatible, sustainable, and tuneable for various medical and life science applications.
- What are the primary applications for UPM's products?
- Applications include 3D cell culture, drug discovery and screening, cell storage and transportation, 3D bioprinting, tissue engineering, advanced wound care, implants, personalized medicine, and novel drug formulations.
- What quality standards does UPM Biomedicals maintain?
- UPM Biomedicals manufactures clinical products under the ISO 13485 quality management system, ensuring compliance with medical device manufacturing standards.
- What is FibGel and when was it launched?
- FibGel is the world's first injectable nanocellulose hydrogel for permanent implantable medical devices, launched in October 2024. It is made from birch wood cellulose and water only, offering a safe, sustainable, and biocompatible alternative for medical device developers.
- Does UPM Biomedicals collaborate with other organizations?
- Yes, UPM Biomedicals has formed strategic collaborations, including a partnership with CELLINK for groundbreaking 3D bioprinting developments that combines UPM's nanocellulose biomaterials expertise with CELLINK's bioprinting methodology experience.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
